Thursday, June 8, 2017

Oncogene - Table of Contents alert Volume 36 Issue 23

If you are unable to see the message below, click here to view.


Volume 36, Issue 23 (June 2017)

In this issue
Original Articles
Letters to the Editor

Also new
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Celebrating 30 years of Oncogene — 1987 to 2017

Thank you to the editors, board members, contributors, reviewers and readers, past and present for their invaluable contributions, and for bringing the journal to this milestone. 

Watch our anniversary video showing a brief impact overview >>>



Rho GTPases: Anti- or pro-neoplastic targets?

I Zandvakili, Y Lin, J C Morris and Y Zheng

Oncogene 2017 36: 3213-3222; advance online publication, December 19, 2016; 10.1038/onc.2016.473

Abstract | Full Text

Original Articles


Analysis of DNA methylation in single circulating tumor cells

C F Pixberg, K Raba, F Müller, B Behrens, E Honisch, D Niederacher, H Neubauer, T Fehm, W Goering, W A Schulz, P Flohr, G Boysen, M Lambros, J S De Bono, W T Knoefel, C Sproll, N H Stoecklein and R P L Neves

Oncogene 2017 36: 3223-3231; advance online publication, January 9, 2017; 10.1038/onc.2016.480

Abstract | Full Text

Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma

M Amit, S Na'ara, L Leider-Trejo, Y Binenbaum, N Kulish, E Fridman, A Shabtai-Orbach, R J Wong and Z Gil

Oncogene 2017 36: 3232-3239; advance online publication, January 16, 2017; 10.1038/onc.2016.483

Abstract | Full Text

miR-19a promotes colitis-associated colorectal cancer by regulating tumor necrosis factor alpha-induced protein 3-NF-κB feedback loops

T Wang, X Xu, Q Xu, J Ren, S Shen, C Fan and Y Hou

Oncogene 2017 36: 3240-3251; advance online publication, December 19, 2016; 10.1038/onc.2016.468

Abstract | Full Text

PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma

J Delyon, A Servy, F Laugier, J André, N Ortonne, M Battistella, S Mourah, A Bensussan, C Lebbé and N Dumaz

Oncogene 2017 36: 3252-3262; advance online publication, January 16, 2017; 10.1038/onc.2016.469

Abstract | Full Text

Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia OPEN

E J Pomeroy, L A Lee, R D W Lee, D K Schirm, N A Temiz, J Ma, T A Gruber, E Diaz-Flores, B S Moriarity, J R Downing, K M Shannon, D A Largaespada and C E Eckfeldt

Oncogene 2017 36: 3263-3273; advance online publication, December 19, 2016; 10.1038/onc.2016.471

Abstract | Full Text

Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma OPEN

C Worrall, N Suleymanova, C Crudden, I Trocoli Drakensjö, E Candrea, D Nedelcu, S-I Takahashi, L Girnita and A Girnita

Oncogene 2017 36: 3274-3286; advance online publication, January 16, 2017; 10.1038/onc.2016.472

Abstract | Full Text

6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells

S Ros, J Flöter, I Kaymak, C Da Costa, A Houddane, S Dubuis, B Griffiths, R Mitter, S Walz, S Blake, A Behrens, K M Brindle, N Zamboni, M H Rider and A Schulze

Oncogene 2017 36: 3287-3299; advance online publication, January 16, 2017; 10.1038/onc.2016.477

Abstract | Full Text

Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera

T Tsuruta-Kishino, J Koya, K Kataoka, K Narukawa, Y Sumitomo, H Kobayashi, T Sato and M Kurokawa

Oncogene 2017 36: 3300-3311; advance online publication, January 9, 2017; 10.1038/onc.2016.478

Abstract | Full Text

FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation

H Zhou, Y Liu, R Zhu, F Ding, Y Wan, Y Li and Z Liu

Oncogene 2017 36: 3312-3321; advance online publication, January 9, 2017; 10.1038/onc.2016.479

Abstract | Full Text

KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth OPEN

M Riverso, V Montagnani and B Stecca

Oncogene 2017 36: 3322-3333; advance online publication, January 9, 2017; 10.1038/onc.2016.481

Abstract | Full Text

Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition

H S Kim, M Jung, H N Kang, H Kim, C-W Park, S-M Kim, S J Shin, S H Kim, S G Kim, E K Kim, M R Yun, Z Zheng, K Y Chung, J Greenbowe, S M Ali, T-M Kim and B C Cho

Oncogene 2017 36: 3334-3345; advance online publication, January 16, 2017; 10.1038/onc.2016.486

Abstract | Full Text

MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia OPEN

K H M Prange, A Mandoli, T Kuznetsova, S-Y Wang, A M Sotoca, A E Marneth, B A van der Reijden, H G Stunnenberg and J H A Martens

Oncogene 2017 36: 3346-3356; advance online publication, January 23, 2017; 10.1038/onc.2016.488

Abstract | Full Text

Letters to the Editor


CIP2A confirms its prognostic value in triple-negative breast cancer

I Cristóbal, S Zazo, B Torrejón, M Pedregal, J Madoz-Gúrpide, A Lluch, P Eroles, A Rovira, J Albanell, J García-Foncillas and F Rojo

Oncogene 2017 36: 3357-3358; advance online publication, January 9, 2017; 10.1038/onc.2016.474

Full Text

LOGO webcasts

Join us for our upcoming webcast followed by live Q&A: 

Presented by BioPharma Dealmakers

Date: Tuesday, 13 June, 2017
Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST


Sponsored by: Immunomic Therapeutics, Inc., | IsoPlexis | Merus N.V. | Actinium Pharmaceuticals, Inc.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: